SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors rally behind the potential for global commercialization and the anticipation of upcoming clinical data, creating a highly volatile environment marked by intense speculation of a short squeeze. The community is focused on the founder's recent communications regarding global expansion efforts, which many interpret as a strategic push to bypass regulatory hurdles and accelerate market entry.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to a major earnings beat and raised guidance that triggered a surge in institutional interest and multiple analyst price target upgrades. The community is actively debating whether this represents a sustainable AI-driven structural shift or an overextended bubble, with many traders watching closely for profit-taking signals.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors react to a recent earnings report that exceeded revenue expectations through high-margin licensing deals, even as community sentiment remains polarized over executive compensation and the company's long-term commercial strategy. The discourse is heavily focused on whether management's push for new equity-based incentives is justified given the stock's historical performance, while active discussions highlight potential breakthroughs in pipeline candidates and the impact of activist pressure on future corporate governance.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is experiencing heightened volatility and intense debate among retail traders as the community speculates on potential catalysts like NBA sports rights, Disney-backed integration efforts, and upcoming earnings results. While some investors see significant upside potential tied to profitability targets and institutional interest, others are wary due to the stock's history of post-earnings sell-offs and lingering frustration over dilution and management decisions.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending following a strong quarterly earnings report that highlighted significant revenue growth, expanded gross margins, and positive momentum in defense and AI edge-computing sectors. Community discussion is focused on the company's strategic pivot toward ruggedized compute solutions for defense and autonomy, with many investors anticipating long-term re-rating potential fueled by bookings growth and defense contract opportunities.

Hut 8 Corp. engages in the development and operation of data centers at scale, supporting AI, high-performance computing (HPC), ASIC compute, and other energy-intensive technology applications. It operates through the following segments: Power, Digital Infrastructure, Compute, and Others. The Power segment manages the origination, development, and management of powered land and energy infrastructure. The Digital Infrastructure refers to the development, ownership, and operation of facilities designed to support next-generation, energy-intensive technology application. The Compute segment deals with operating businesses that deploy and monetize compute assets across next-generation energy-intensive technology. The Others segment offers equipment sales and repairs. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is currently at the center of investor focus following a massive 15-year, $9.8 billion AI data center lease, which has sparked a strong rerating narrative as the company shifts from a crypto miner to an AI infrastructure leader. While some community members remain skeptical of the transition and the reliance on major hyperscalers, bulls are aggressively highlighting the stock's long-term potential, leading to intense debates over its valuation and recent parabolic price action.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending as the stock surges following a strong earnings report where improved gross margins and robust future guidance overshadowed a revenue miss. The community is actively debating the stock's potential for a massive short squeeze and long-term re-rating, contrasting the company's valuation against its AI sector peers.

Aurora Innovation, Inc. engages in the design and development of automobile hardware, software, and provision of data services. It offers the Aurora Driver which allows a vehicle to drive itself. The company was founded by Christopher Urmson, Sterling Anderson and James Andrew Bagnell in 2017 and is headquartered in Pittsburgh, PA.

Aurora Innovation Inc - Ordinary Shares - Class A

Aurora Innovation is experiencing significant upward momentum driven by a major partnership expansion with Hirschbach to deploy hundreds of autonomous trucks, signaling a shift from research to large-scale commercialization. Investors are actively discussing the potential for a short squeeze, citing high short interest and massive insider buying that bolsters confidence in the company's long-term scale and execution.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is surging as investors pivot toward its potential as an AI infrastructure and power-centric datacenter play, bolstered by a significant expansion in its partnership with AMD. Community sentiment is highly active, with traders closely monitoring technical resistance levels while debating the long-term strategic transformation from pure Bitcoin mining into a critical AI power provider.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is driving significant buzz as the company shifts from developmental milestones to real-world commercial viability, highlighted by high-profile flight demonstrations in New York City and a strong institutional backing. While the community remains divided between long-term investors tracking FAA certification progress and skeptics focused on cash burn and technical hurdles, active discussions are fixated on the upcoming earnings call and the potential for the company to solidify its position as the leader in urban air mobility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Does Cobenfy Have the Potential to Become a Top Drug for BMY?

BMY's Cobenfy gains traction with $155M in 2025 sales, outpacing peers and showing strong uptake as Bristol Myers eyes new indications and growth.

<ul class="summary-bullets"><li>Reviva to use the proceeds for its Phase 3 RECOVER-2 trial for brilaroxazine to treat schizophrenia.</li><li>The company had earlier said that it plans to launch the RECOVER-2 Phase 3 trial in the first half of 2026.</li><li>Reviva implemented a 1-for-20 reverse share split on March 9.</li></ul>Shares of Reviva Pharmaceuticals Holdings (RVPH) plummeted more than 40% in pre-market trading on Thursday, after the company priced its public offering to raise about $10 million.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/RVPH">RVPH shares</a> would fall to a record low.<h2 class="st-heading-2">Offering At 20% Discount</h2>The offering consists of 6.67 million shares, as well as Series G and Series H warrants to purchase an equal number of shares, all priced at a combined $1.50 per share, for total gross proceeds of about $10 million. This represents a 20% discount on the stock’s closing price of $1.87 on Wednesday.Both warrants are immediately exercisable: Series G is valid for 5 years, and Series H expires in 12 months, the pharmaceutical company said. The offering is expected to close around March 20, 2026.Reviva said it plans to use the proceeds, along with existing cash, to support research and development, including its Phase 3 RECOVER-2 trial for brilaroxazine to treat schizophrenia. Funds will also be used for working capital and general corporate needs.<h2 class="st-heading-2">Reviva To Begin A Second Phase 3 Trial In First Half Of 2026</h2>In January, the U.S. Food and Drug Administration (FDA) recommended conducting a second Phase 3 trial for its schizophrenia drug candidate to get additional efficacy and safety data before submitting a New Drug Application (NDA).The company had earlier said that it plans to launch the RECOVER-2 Phase 3 trial in the first half of 2026, subject to funding. Reviva said existing data showed strong efficacy across key symptoms of schizophrenia and a favorable safety profile, with over 900 patients treated so far.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the pre-market slump, retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier.Chatter was mixed. One user said the stock’s upside looks “amazing” and the company may require $60 to $70 million to complete the study.<stembedurl>https://stocktwits.com/Blaze321/message/647942525</stembedurl>Another user said there was “no chance” of raising the required funds.<stembedurl>https://stocktwits.com/Gropius/message/647911923</stembedurl>Reviva had announced a 1-for-20 reverse share split earlier this month, with the stock trading on an ex-split basis from March 9.For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

Why Did RVPH Stock Crash 40% In Pre-Market Today?

Reviva Pharmaceuticals Holdings company priced its $10 million offering at a 20% discount from Wednesday’s close.

Equity

The company priced its $10 million offering at a 20% discount from Wednesday’s close.

Investors Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders acquired 25,745 call options on the...

<ul class="summary-bullets"><li>FDA recommended that Reviva conduct a second Phase 3 clinical trial to generate additional efficacy data and expand brilaroxazine’s safety database.</li><li>The company plans to initiate the RECOVER-2 Phase 3 registrational trial in the first half of 2026.</li><li>The company’s current estimates project that the trial cost will be around $60 million.</li></ul>Shares of Reviva Pharmaceuticals Holdings (RVPH) plunged more than 50% on Tuesday after the FDA called for an additional Phase 3 trial of the company’s schizophrenia treatment drug, dealing a significant setback to its regulatory timeline.In written feedback, the FDA recommended that Reviva conduct a second Phase 3 clinical trial to generate additional efficacy data and further expand brilaroxazine’s safety database before submitting a new drug application (NDA).Subject to sufficient financing, the company plans to initiate the RECOVER-2 Phase 3 registrational trial in the first half of 2026. The study is expected to mirror the design of the completed RECOVER Phase 3 trial. The FDA also provided guidance on data analysis and presentation, as well as requirements for animal pharmacokinetics, human abuse potential, and renal and hepatic impairment studies.<h2 class="st-heading-2">Cost Of The Trial</h2>According to an SEC filing, the company’s current estimates project the trial cost at around $60 million, consisting of roughly $35 million in direct trial costs and approximately $24 million in general and administrative expenses.The FDA’s recommendation follows its review of two completed randomized, double-blind, placebo-controlled studies, including one Phase 2 and one Phase 3 trial with a one-year open-label extension. Across these studies, brilaroxazine demonstrated efficacy across major schizophrenia symptom domains, including negative symptoms, in 790 participants, Reviva added.At a meeting on December 18, Reviva shareholders approved the reverse stock split charter amendment, allowing the board to implement a 1-for-2 to 1-for-20 split at its discretion before Dec. 31, 2026. Companies generally use a reverse split to meet the $1.00 minimum bid price requirement under Nasdaq listing compliance.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/RVPH">RVPH</a> on Stocktwits remained in the ‘bearish’ territory over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img style="aspect-ratio:919/97;" src="https://news.stocktwits-cdn.com/RVPH_png_6f1a479b84.webp" alt="RVPH.png" width="919" height="97"><figcaption>RVPH's Sentiment Meter and Message Volumes at 10:15 a.m. ET on Dec. 23, 2025 | Source: Stocktwits</figcaption></figure>One user opined on how the company could raise funds to cover the trial costs.<stembedurl>https://stocktwits.com/jgo1/message/639964998</stembedurl>Another user speculated about the trial timelines.<stembedurl>https://stocktwits.com/hawkeye45691/message/639962383</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/spot-silver-crosses-70-an-ounce-for-the-first-time/cLep81RREuz">Spot Silver Crosses $70 An Ounce For The First Time</a> For updates and corrections, email newsroom[at]stocktwits[dot]com

Representative image of stock price falling. (Photo by Yuichiro Chino/Getty Images)

Why Did RVPH Stock Crash 50% Today?

The company announced that the FDA called for an additional Phase 3 trial of its schizophrenia treatment drug.

Reviva Pharmaceuticals (NASDAQ:RVPH) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and issued a $2.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday...

Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock traders acquired 27,891 call options on the...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of "Moderate Buy" by Brokerages

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine brokerages that are currently covering the company, MarketBeat.com...

Brokers Offer Predictions for RVPH FY2025 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Analysts at Chardan Capital issued their FY2025 earnings per share estimates for Reviva Pharmaceuticals in a research note issued...

Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.

&nbsp;The stock market rally stalled on Tuesday, with the S&amp;P 500 Index retreating from its record closing high of 6,001.35. The weakness could be due to traders taking profit off their recent gains and shifting to the sidelines ahead of some key Main Street data on inflation and retail sales.IT, real-estate and industrial stocks served as drags, while the strength in the consumer discretionary and financial spaces offset some of the weakness.As the market pauses, here’s a compilation of stocks retailers on the Stocktwits platform are most bullish and bearish about:Most BullishNeuronetics, Inc. ($STIM)Pennsylvania-based Neuronetics, a commercial-stage med-tech company has seen its shares plunge hard following its third-quarter earnings announcement. The loss per share of $0.44 grossly missed the consensus loss estimate of $0.23, and revenue of $18.53 million also trailed the $19.14 million.The stock plunged about 40% but retail is ‘extremely” bullish on the stock.Zscaler, Inc. ($ZS)Shares of Zscaler, a San Jose, California-based cybersecurity company, rose nearly 3% on&nbsp;Tuesday following an announcement regarding its “Zero Trust Segmentation” solution.&nbsp;This solution will “provide a more secure, agile and cost-effective means to connect users, devices, and workloads across and within globally distributed branches, factories, campuses, data centers, and public clouds,” the company said.Axsome Therapeutics, Inc. ($AXSM)New York-based Axsome, which focuses on central nervous system disorders, reported a double beat for the third quarter. The stock rose over 6% following the quarterly results. The company has an FDA decision date in late January for its migraine treatment candidate.&nbsp;“We expect a busy end to the year with several clinical catalysts anticipated, including a planned simultaneous release of topline results from the ongoing Phase 3 ADVANCE-2 and ACCORD-2 trials of AXS-05 in Alzheimer’s disease agitation in the fourth quarter,” said CEO Herriot Tabuteau.Bitcoin Depot, Inc. ($BTM)Atlanta, Georgia-based Bitcoin Depot provides users with simple and efficient ways to convert cash into Bitcoin ($BTC.X).&nbsp;The company’s shares are pulling back after Monday’s 54% jump but retail held on to its bullish bias.MediciNova, Inc. ($MNOV)La Jolla, California-based MediciNova, said it was notified by Sanofi ($SNY) that the Sanofi/Novartis AG ($NVS) litigation was settled. This provides for MediciNova receiving&nbsp;a certain amount of monetary damages through this settlement. MediciNova’s stock jumped following the news, triggering positive reaction from the retail crowd.Most BearishReviva Pharmaceuticals, Holdings, Inc. ($RVPH)Reviva, a late-stage&nbsp;pharma developing therapies in the areas of central nervous system, inflammatory and cardiometabolic diseases, announced a positive update on the enrollment for the ongoing 1-year open-label extension study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia. The stock climbed about 33% on Tuesday but retail sentiment was at a rock bottom.Pagaya Technologies Ltd. ($PGY)Israel-based Pagaya, a provider of&nbsp;financial products and services, reported a loss for the third quarter, which was much wider than expected. The stock slumped over 35%. Some among the retailers called outt the company a “fraud.Aldeyra Therapeutics, Inc. ($ALDX)Lexington, Massachusetts-based Aldeyra is a biotech focusing on therapies for immune-mediated and metabolic diseases. The shares of the company plunged on Tuesday on just about average volume.&nbsp;Retailers on the Stocktwits platform fretted over poor data for its dry eye disease product candidate.&nbsp;Quantum-Si Inc. ($QSI)Protein sequencing company Quantum-Si’s shares plunged over 22% on Tuesday after the&nbsp; Branford, Connecticut-based company reported its third-quarter results.ViaSat, Inc. ($VSAT)Shares of Carlsbad, California-based ViaSat have been ailing ever since the satellite telecommunications reported its financial results for the fiscal year 2025 second-quarter results last Thursday. This, in turn, has dented retail sentiment.&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/euphoric-run-of-tesla-stock-catalyzed-by-election-result-stalled/cJ40dh1ROF">Tesla Stock’s Post-Election Rally Stalls But Analyst Talks Up His $500 Bull-Case Scenario: Retail Mood Stays Sou</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

A slew of biopharma stocks made big moves on Tuesday. 

10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday

Earnings largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.

Reviva Pharmaceuticals Holdings Inc.

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

RVPH
Reviva Pharmaceuticals Holdings Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RVPH News

RVPHReviva Pharmaceuticals Holdings Inc.